Jeffrey M. Turner, MD, shares insights from Kidney Week that are shaping his practice, emphasizing earlier intervention in immunoglobulin A nephropathy to preserve kidney function over decades rather than focusing solely on short-term outcomes. He describes underuse of newer therapies and plans to use BAFF/APRIL inhibitors and complement inhibitors more frequently in appropriate patients.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jeffrey
Contact Jeffrey, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack